- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1479-5876
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Novel combination therapies for BRAF-mutant melanoma ; volume:13 ; number:1 ; day:15 ; month:1 ; year:2015 ; pages:1 ; date:12.2015
Journal of translational medicine ; 13, Heft 1 (15.1.2015), 1, 12.2015
- Creator
-
McArthur, Grant A.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/1479-5876-13-S1-K6
- URN
-
urn:nbn:de:1111-2016041451310
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:01 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- McArthur, Grant A.
- SpringerLink (Online service)
Other Objects (12)
Optimizing the treatment of BRAF mutant melanoma
WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma
Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis
Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned
Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma
The future of combination therapies in advanced melanoma
ROCK 1 is a potential combinatorial drug target for BRAF mutant melanoma
Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma
Melanoma: A model for testing new agents in combination therapies
Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma
Optimizing the treatment of BRAF mutant melanoma
WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma
Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis
Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned
Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma
The future of combination therapies in advanced melanoma
ROCK 1 is a potential combinatorial drug target for BRAF mutant melanoma
Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma
Melanoma: A model for testing new agents in combination therapies
Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma
Optimizing the treatment of BRAF mutant melanoma
WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma
Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis
Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned
Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma
The future of combination therapies in advanced melanoma
ROCK 1 is a potential combinatorial drug target for BRAF mutant melanoma
Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma
Melanoma: A model for testing new agents in combination therapies
Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma